Key Findings
In a Phase 1b clinical trial, CTX310 demonstrated a mean reduction of 63% in triglycerides (TG) and 65% in circulating ANGPTL3 protein at Day 30. These results were observed in a cohort of 10 participants with severe hypertriglyceridemia (sHTG) who had a median baseline TG level above 1,000 mg/dL. Additionally, the treatment resulted in mean reductions of 51% in non-HDL-C, 23% in apolipoprotein B (ApoB), and 16% in LDL-C (from a mean baseline of 60 mg/dL). Reductions in ANGPTL3 and TG were maintained in participants followed for at least 90 days.
Technical Details
CTX310 is an investigational in vivo CRISPR/Cas9 gene editing therapy targeting angiopoietin-like protein 3 (ANGPTL3). The Phase 1b multicenter, open-label trial utilized a weight-based flat dosing approach: 40 mg for participants below 85 kg and 50 mg for those 85 kg or above, approximating the 0.8 mg/kg dose from Phase 1a. One participant received a dose of 56.5 mg.
The sHTG cohort consisted of 10 participants with fasting serum TG above 500 mg/dL. All participants had diabetes; 30% had a history of pancreatitis, and 20% had clinical atherosclerotic cardiovascular disease. Safety data indicated no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases (AST or ALT). One participant experienced a Grade 2 infusion-related reaction that resolved.
Background & Context
The data were presented at the AHA Scientific Sessions 2026, building upon Phase 1a results and one-year durability data published in The New England Journal of Medicine. The U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for the treatment of sHTG and for patients with elevated low-density lipoprotein cholesterol (LDL-C).
Significance & Outlook
Severe hypertriglyceridemia is associated with increased risks of acute pancreatitis and cardiovascular disease, often remaining uncontrolled despite current therapies. No events of acute pancreatitis were reported during this study. CRISPR Therapeutics is continuing the Phase 1b trial across multiple lipid disorders with ongoing sites in the United States, United Kingdom, Australia, and New Zealand.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



